Hims & Hers Acquires U.S.-based Peptide Facility; No Financial Terms Disclosed

Hims & Hers Health, Inc. Class A +10.54% Pre

Hims & Hers Health, Inc. Class A

HIMS

20.76

21.15

+10.54%

+1.88% Pre

The acquisition will strengthen the long-term durability of the company's domestic supply chain, helping to ensure Americans can consistently access personalized medications

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.